MD PhD

Kevin is the Founder, Chief Executive Officer and Chairman of the Board. Over the course of his career, he has been committed to advancing the development of breakthrough treatments with particular emphasis on translational medicine. Most recently, Kevin served as Senior VP and Chief Medical Officer of Eusol Biotech, a clinical stage company focused on developing therapeutics for neurological diseases. Prior to Eusol, Kevin served as Director of Translational Medicine at the Development Center for Biotechnology (DCB), Taiwan, where he led an initiative to implement translational medicine strategy across drug development stages. He played a key role in strategic planning and building the immune-oncology portfolio, and led the development of anti-TIM3 and CSF1R inhibitor preclinical candidates. Prior to DCB, Kevin was a Principal Scientist at GSK’s Neuroimmunology Discovery Performance Unit in Shanghai where he led a project team and successfully moved a novel drug discovery project from target identification and validation to lead optimization. He also served on global development teams, leading the biomarker and translational studies for a phase 2 clinical trial. Prior to joining GSK, Kevin was as an Assistant Investigator at the Gladstone Institutes’ Translational Research Center in San Francisco. Kevin actively participated in a multi-million-dollar academia-industry collaborative project with Merck & Co., Inc. for the development of small molecule drugs for treating Alzheimer’s disease.Kevin has authored or co-authored several peer-reviewed publications in leading journals including Cell, Nature Medicine and Nature Communications. Kevin earned his M.D. and Ph.D. from National Yang-Ming University and completed postdoctoral training at Baylor College of Medicine and Howard Hughes Medical Institute at Houston, Texas.